NCT06879730Recruiting
Retrospective Evaluation of Minimally-Invasive Surgical Strategies in Ovarian Neoplasms (REMISSION Study)
Source: ClinicalTrials.gov · Last updated 17 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This observational study aims to evaluate the outcomes of patients with early-stage epithelial ovarian cancer who are treated with minimally invasive surgery (such as laparoscopic or robotic surgery). Specifically, the study will look at: 1. Post-Surgery Complications * What is the rate of complications within 30 days after surgery? * How often do patients require readmission to the hospital, re-operation, or conversion to open surgery? 2. Cancer Outcomes * What is the rate of cancer upstaging (when the cancer spreads to a more advanced stage during surgery for example because of an intra-operative ovarian cyst rupture)? * What are the overall survival and disease-free survival rates for patients treated with minimally invasive surgery? Researchers will compare two groups of patients: Group 1: Patients with early-stage ovarian cancer treated with minimally invasive surgery. Group 2: Patients with early-stage ovarian cancer treated with open surgery. The goal is to see if there are any differences in post-surgery complications, recovery, and cancer outcomes between the two groups. Fertility-Sparing Treatment: The study will also compare patients who are undergoing fertility-sparing treatments for early-stage ovarian cancer. Two subgroups will be looked at: * Patients receiving fertility-sparing surgery through a minimally invasive procedure. * Patients receiving fertility-sparing surgery through an open surgery. The same outcomes (complications, survival, etc.) will be assessed and compared between these two groups as well.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1500 (estimated)
- First submitted
- 1 Dec 2024
- Start date
- 15 May 2024
- Primary completion date
- Feb 2026
- Lead sponsor
- Jvan Casarin, MD PhD
- Diseases
- Ovarian cancer, Childhood cancers
- NCT number
- NCT06879730
What you commit to
- Study type: Observational
- Planned participants: 1500
- From 15 May 2024 to the primary completion date, Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have not performed a complete surgical staging
- Patients who underwent neoadjuvant chemotherapy
Other
- Patients with invasive synchronous tumor
- Patients with no informed consent
- Patients with ASA class score of 4 or 5
Who the study is looking for
- Patients with apparent early-stage epithelial ovarian cancer at preoperative evaluation
- Patients who underwent surgery between January 2014 and December 2023
- Patients who underwent open or minimally invasive surgical staging (Laparoscopic or Robotic-assisted approach) or restaging procedure
- Patients with final pathology report of Epithelial Ovarian Cancer
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ospedale Filippo del Ponte Coordinator of this site? Confirm its status | Varese | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.